• Michon P, Dumas P
  • PV 250
  • Novembre 2004

a - Argyle DJ. Nonsteroidal anti-inflammatory drugs in cancer management. The North American Veterinary Conference proceedings. 2004:690.
b - Lascelles BD. NSAID's and cancer – is there any potentiel ? The North American Veterinary Conference proceedings. 2004;2:869.
c - Lascelles BD. Pain and cancer. Masterclass North American Veterinary Conference. 2003: présentation orale (version américaine longue des PdJ Virbac appelée "Meet the Professor Luncheon").

À lire également
a - Bensignor E. Nouveautés du traitement médical des tumeurs cutanées. L'Action Vétérinaire. 1997;1404:19-23.

1- D'Alessandro T, Prasain J, Benton MR et coll. Polyphenols, inflammatory response, and cancer prevention: chlorination of isoflavones by human neutrophils. J. Nutr. 2003;133(11Suppl1):3773S-3777S.
2- Barsanti JA. Piroxicam for bladder cancer. J. Vet. Intern. Med. 1995;9(2):113-114.
3- Boutemmine D, Bouchard N, Boerboom D et coll. Molecular characterization of canine prostaglandin G/H synthase-2 and regulation in prostatic adenocarcinoma cells in vitro. Endocrinology. 2002;143(3):1134-1143.
4- Breau JL, Morere JF, Israel L. Régression et ralentissement de croissance de métastases pulmonaires chez l'homme par le piroxicam, un inhibiteur de la synthèse des prostaglandines. Bull. Cancer. 1989;76(3):321-328.
5- Cervi D, Truong AH, Lee JS et coll. Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib. Oncogene. 2004;23(13):2305-2314.
6- Chandrasekharan NV, Dai H, Roos KL et coll. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 2002;99(21):13926-13931.
7- Chiu LC, Tong KF, Ooi VE. Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein. Oncol. Rep. 2004;11(1):225–230.
8- Chun R, Knapp DW, Widmer WR et coll. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J. Amer. Vet. Med. Assn. 1996;209(9):1588-1591.
9- Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug. Metabol. Drug. Interact. 2000;17(1-4):109-157.
10-Davis TW, O'Neal JM, Pagel MD et coll. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 2004;64(1):279-285.
13- Goulet AC, Einsphar JG, Alberts DS et coll. Analysis of cyclooxygenase 2 (cox-2) expression during malignant melanoma progression. Cancer Biol. Ther. 2003;2(6):713-718.
14- Henry CJ, McCaw DL, Turnquist SE et coll. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin. Cancer Res. 2003;9(2):906-911.
15- Inase N, Levine TM, Lazarus SC. Mitogen-inducible prostaglandin G/H synthase is expressed in canine mastocytoma cells. Am. J. Respir. Cell. Mol. Biol. 1993;9(5):526-532.
16- Karaguni IM, Herter P, Debruyne P et coll. The new sulindac derivative IND 12 reverses Ras-induced cell transformation. Cancer Res. 2002;62(6):1718-1723.
17- Kelloff GJ, Crowell JA, Boone CW et coll. Clinical development plan: sulindac. J. Cell. Biochem. Suppl. 1994;20:240-251.
18- Kelloff GJ, Crowell JA, Boone CW et coll. Clinical development plan: piroxicam. J. Cell. Biochem. Suppl. 1994;20:219-230.
19- Khan KN, Knapp DW, Denicola DB et coll. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am. J. Vet. Res. 2000;61(5):478-481.
20- Khan KN, Stanfield KM, Trajkovic D et coll. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Veterinary Pathology. 2001;38:116-119.
22- Knapp DW, Richardson RC, Bottoms GD et coll. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother. Pharmacol. 1992;29(3):214-218.
23- Knapp DW, Richardson RC, Chan TC et coll. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med. 1994;8(4):273-278.
24- Knapp DW, Chan TC, Kuczek T et coll. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am. J. Vet. Res. 1995;56(6):801-805.
25- Knapp DW, Glickman NW, Widmer WR et coll. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother. Pharmacol. 2000;46(3):221-226.
26- Knapp DW, Glickman NW, Mohammed SI et coll. Antitumor effects of piroxicam in spontaneous canine invasive urinary bladder cancer, a relevant model of human invasive bladder cancer. Adv. Exp. Med. Biol. 2002;507:377-380.
27- Knottenbelt CM, Simpson JW, Tasker S et coll. Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. J. Small Anim. Pract. 2000;41(9):393-397.
28- Knottenbelt CM, Simpson JW, Chandler ML. Neutrophilic leucocytosis in a dog with a rectal tumour. J. Small Anim. Pract. 2000;41(10):457-460.
29- Koki AT, Khan NK, Woerner BM et coll. Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers. Prostaglandins Leukot. Essent. Fatty Acids. 2002;66(1):13-18.
30- Koki AT, Khan NK, Woerner BM et coll. Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 2002;507:177-184.
31- Kulkarni S, Rader JS, Zhang F et coll. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 2001;7(2):429-434.
32- Lanza-Jacoby S, Miller S, Flynn J et coll. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol. Biomarkers Prev. 2003;12(12):1486-1491.
35- Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature. 1978;272(5654):634-636.
36- Lupulescu A. Effect of prostaglandins on skin tumorigenesis. Experientia. 1978;34(6):785-788.
37- Lupulescu A. Enhancement of carcinogenesis by prostaglandins in male albino Swiss mice. J. Natl. Cancer Inst. 1978;61(1):97-106.
38- Magnol JP, Marchal T, Delisle F et coll. Cancérologie clinique du chien. Saint Pierre La Palud : Th. Marchal. 1998:421.
40- McEntee MF, Cates JM, Neilsen N. Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet. Pathol. 2002;39(4):428-36.
41- Mohammed SI, Bennett PF, Craig BA et coll. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer. Res. 2002;62(2):356-358.
42- Mohammed SI, Craig BA, Mutsaers AJ et coll. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol. Cancer Ther. 2003;2(2):183-188.
43- Mutsaers AJ, Glickman NW, DeNicola DB et coll. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. J. Amer. Vet. Med. Assn. 2002;220(12):1813-1817.
44- Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J. Vet. Intern. Med. 2003;17(2):136-144.
46-Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain. 2001;90(1-2):191-199.
47- Pollard M, Luckert PH. Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett. 1984;25(2):117-121.
48- Ruegg C, Dormond O. Suppression of tumor angiogenesis by nonsteroidal anti-inflammatory drugs: a new function for old drugs. ScientificWorldJournal. 2001;1(12):808-811.
50- Revillard JP. Immunologie. De Boeck Université Ed. Paris. 2001:221.
51- Rowlinson SW, Kiefer JR, Prusakiewicz JJ et coll. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem. 2003;278(46):45763-45769.
52- Schmidt BR, Glickman NW, DeNicola DB et coll. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J. Amer. Vet. Med. Assn. 2001;218(11):1783-1786.
53- Tremblay C, Doré M, Bochsler PN et coll. Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. J. Natl. Cancer Inst. 1999;91(16):1398-1403.
54- Wilgus TA, Koki AT, Zweifel BS et coll. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol. Carcinog. 2003;38(2):49-58.
56- Zweifel BS, Davis TW, Ornberg RL et coll. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 2002; 62(22):6706-6711.

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d’intérêts.X
Pour en savoir plus et paramétrer les cookies...